Silo Pharma, Inc. (Nasdaq: SILO) announced a share repurchase program to acquire up to $1 million of its common stock. The company had 13,318,273 shares outstanding as of November 13, 2025. CEO Eric Weisblum stated the buyback program aims to capture additional value for shareholders. The timing and number of shares repurchased will depend on market conditions. Silo Pharma focuses on developing therapies for stress-induced psychiatric disorders, chronic pain, and CNS diseases. The company’s portfolio includes programs for PTSD, fibromyalgia, Alzheimer’s, and multiple sclerosis. For more information, visit silopharma.com. Contact [email protected] or call (800) 705-0120 for inquiries.

Read more at GlobeNewswire: Silo Pharma Announces Share Buyback Program